Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Lymphoma, Large B-Cell, Diffuse 4Multiple Myeloma 3Lymphoma, Non-Hodgkin 3Lymphoma, Follicular 3Lymphoma 3Endometrial Neoplasms 3Ovarian Neoplasms 2Leukemia, Lymphocytic, Chronic, B-Cell 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Thyroid Neoplasms 1Stomach Neoplasms 1Rectal Neoplasms 1Prostatic Neoplasms 1Platinum-Refractory Fallopian Tube Carcinoma 1Pancreatic Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Melanoma 1Malignant Solid Neoplasm 1Lymphoma, Mantle-Cell 1Lymphoma, B-Cell, Marginal Zone 1Lung Neoplasms 1Leukemia, Lymphoid 1Hematologic Neoplasms 1Glioma 1Gallbladder Neoplasms 1Estrogen Receptor Positive 1Esophageal Neoplasms 1

Interventions

fludarabine 4Rituximab 4ibrutinib 3blinatumomab 3Whole-Body Irradiation 3Tacrolimus 3Peripheral Blood Stem Cell Transplantation 3Mycophenolic Acid 3Melphalan 3Lenalidomide 3Cyclophosphamide 3Busulfan 3Bendamustine Hydrochloride 3fludarabine phosphate 2Patient Reported Outcome Measures 2Mesna 2venetoclax 1sargramostim 1pirtobrutinib 1ofatumumab 1mocetinostat 1lirilumab 1copanlisib 1Thiotepa 1Sirolimus 1RFT5-SMPT-dgA immunotoxin 1Mitoxantrone 1Methotrexate 1Granulocyte-Macrophage Colony-Stimulating Factor 1Granulocyte Colony-Stimulating Factor 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Leukemia, Lymphoid × copanlisib × Clear all
NCT04155840 2022-04-11

Bendamustine and Rituximab in Combination With Copanlisib for the Treatment of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

University of Washington

Phase 2 Terminated
1 enrolled 6 charts
LymphoidOther hematologic neoplasm

Leukemia, Lymphoid, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡